Entrada Therapeutics, Inc.
TRDANASDAQHealthcare● Active
$6.26
$-0.11(-1.73%)
Market Cap$243017056
P/E Ratio—
52W High$16.45
52W Low$4.93
Entrada Therapeutics, Inc. (TRDA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TRDA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $25.42M | $210.78M | $129.01M | $0.00M | $0.00M |
| Cost of Revenue | $4.10M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $21.32M | $210.78M | $129.01M | $0.00M | $0.00M |
| Gross Margin %(computed) | 83.89% | 100.00% | 100.00% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $142.27M | $125.31M | $99.88M | $66.61M | $35.93M |
| G&A Expenses | $41.05M | $38.47M | $32.29M | $30.64M | $15.20M |
| Total Operating Expenses | $177.32M | $163.77M | $132.18M | $97.25M | $51.13M |
| Operating Income | ($156.00M) | $47.01M | ($3.16M) | ($97.25M) | ($51.13M) |
| Operating Margin %(computed) | -613.66% | 22.30% | -2.45% | — | — |
| Interest Income | $0.00M | $19.47M | $15.22M | $2.63M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $2.63M | $0.00M |
| Income Before Tax | ($142.83M) | $66.48M | $12.06M | ($94.62M) | ($51.16M) |
| Income Tax Expense | $0.92M | $0.86M | $18.74M | $0.00M | $0.00M |
| Net Income | ($143.75M) | $65.63M | ($6.68M) | ($94.62M) | ($51.16M) |
| Net Margin %(computed) | -565.48% | 31.13% | -5.18% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.47 | $1.76 | $-0.20 | $-2.79 | $-1.60 |
| Wtd Avg Shares | 41.37M | 37.31M | 33.05M | 31.29M | 31.22M |
| EBITDA | ($142.40M) | $50.78M | ($0.32M) | ($95.35M) | ($50.01M) |
| EBITDA Margin %(computed) | -560.17% | 24.09% | -0.25% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Entrada Therapeutics, Inc. data
About Entrada Therapeutics, Inc. (TRDA) Income Statement
Entrada Therapeutics, Inc. (TRDA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TRDA reported revenue of $0.03B, gross profit of $0.02B (gross margin 83.89%), and net income of ($0.14B) — a net profit margin of -565.48%.
Frequently asked questions
TRDA · 4 questionsEntrada Therapeutics, Inc. (TRDA) reported revenue of $0.03B for 2025, down 87.9% year-over-year.
TRDA revenueTRDA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08